In Billing
Feb 19th, 2018
Effective Jan. 1, 2018, newly approved biosimilar biologicals with a common reference product are no longer grouped into the same billing code. This change was finalized in the 2018 Medicare Physician Fee Schedule final rule. Q5102 Replaced with Two New Codes The April 2018 update to the Medicare Physician Fee Schedule Database (MPFSD) includes three ...
In Billing
May 28th, 2010
Physicians who treat Medicare patients with cancer or a particular HIV-related illness will soon have three additional HCPCS Level II codes they can report on claims for the drugs used in treating their patients. The following HCPCS Level II code is payable under Medicare effective July 1, 2010, when documentation shows medical necessity: Code Description TOS ...
In Coding
Oct 19th, 2009
An Oct. 8 post on TrailBlazer Health Enterprises’ Web site notifies Parts A and B providers that HCPCS Level II code J3420 is no longer covered as a self-administered drug, as indicated on the Self-Administered Drug Exclusions list, effective for service dates on or after Oct. 12. HCPCS Level II Descriptor J3420 Injection, vitamin B-12 ...